Onderzoeker
Gil Awada
- Trefwoorden:Geneeskunde
- Disciplines:Natuurwetenschappen, Ingenieurswetenschappen en technologie, Sociale wetenschappen
Affiliaties
- Medische Oncologie (Departement)
Lid
Vanaf1 sep 2023 → Heden - Laboratorium Moleculaire Oncologie (Onderzoeksgroep)
Lid
Vanaf22 mrt 2021 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf15 nov 2023 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf15 nov 2023 → 15 nov 2023 - Medische Oncologie (Departement)
Lid
Vanaf1 nov 2021 → 31 jul 2023 - Interne Geneeskunde (Departement)
Lid
Vanaf1 sep 2021 → 31 okt 2021 - Medische Oncologie (Departement)
Lid
Vanaf1 aug 2021 → 31 aug 2021 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf8 apr 2019 → 31 jul 2021 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 okt 2017 → 31 jul 2021 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf13 jul 2017 → 18 jun 2021 - Interne Geneeskunde (Departement)
Lid
Vanaf1 aug 2016 → 31 jul 2021 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf4 okt 2015 → 27 apr 2023 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf1 aug 2011 → 24 jun 2015
Publicaties
11 - 20 van 37
- Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy(2021)
Auteurs: Jens Tijtgat, Julia Katharina Schwarze, G Awada, Bart Neyns, Sandrine Aspeslagh
Pagina's: 272-276 - A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT)(2021)
Auteurs: G Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Hendrik Everaert, Bart Neyns
- Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome(2021)
Auteurs: Sim Vermeulen, G Awada, Marleen Keyaerts, Bart Neyns, Hendrik Everaert
Pagina's: 1630-1640 - Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse(2021)
Auteurs: Yanina Jansen, Inneke Willekens, Teofila Seremet, G Awada, Julia Katharina Schwarze, Johan de Mey, Carola Brussaard, Bart Neyns
Pagina's: 1-13 - A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab(2021)
Auteurs: G Awada, Yanina Jansen, Julia Katharina Schwarze, Jens Tijtgat, Lennert Hellinckx, Odrade Gondry, Sim Vermeulen, Sarah Warren, Kelly A Schats, Pieter-Jan van Dam, et al.
Pagina's: 1-18 - Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma(2021)
Auteurs: Bastiaan Sol, Jeroen M.K. de Filette, G Awada, Steven Raeymaeckers, Sandrine Aspeslagh, Corina Andreescu, Bart Neyns, Brigitte Velkeniers-Hoebanckx
Pagina's: 1-5 - Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors(2020)
Auteurs: Julia Katharina Schwarze, G Awada, Louise Cras, Jens Tijtgat, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Bart Neyns
Pagina's: 1-16 - Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)(2020)
Auteurs: G Awada, Laila Ben Salama, Jennifer De Cremer, Julia Katharina Schwarze, Lydia Fischbuch, Laura Seynaeve, Stephanie Du Four, A Vanbinst, Alex Michotte, Hendrik Everaert, et al.
Pagina's: 1-12 - An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma(2020)
Auteurs: Stijn De Keukeleire, Julia Katharina Schwarze, G Awada, Hendrik Everaert, A Vanbinst, Louise Cras, Bart Neyns, Sandrine Aspeslagh
Pagina's: 524-527 - Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab(2020)
Auteurs: Anne Rogiers, Christophe Leys, Justine Lauwyck, Adrian Schembri, G Awada, Julia Katharina Schwarze, Jennifer De Cremer, Peter Theuns, Paul Maruff, Mark De Ridder, et al.